Browse TNIK

Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Recycling endosome. Cytoplasm, cytoskeleton. Note=Associated with recycling endosomes and the cytoskeletal fraction upon RAP2A overexpression.
Domain PF00780 CNH domain
PF00069 Protein kinase domain
Function

Serine/threonine kinase that acts as an essential activator of the Wnt signaling pathway. Recruited to promoters of Wnt target genes and required to activate their expression. May act by phosphorylating TCF4/TCF7L2. Appears to act upstream of the JUN N-terminal pathway. May play a role in the response to environmental stress. Part of a signaling complex composed of NEDD4, RAP2A and TNIK which regulates neuronal dendrite extension and arborization during development. More generally, it may play a role in cytoskeletal rearrangements and regulate cell spreading. Phosphorylates SMAD1 on Thr-322.

> Gene Ontology
 
Biological Process GO:0000186 activation of MAPKK activity
GO:0007009 plasma membrane organization
GO:0007254 JNK cascade
GO:0007256 activation of JNKK activity
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0016055 Wnt signaling pathway
GO:0016358 dendrite development
GO:0022604 regulation of cell morphogenesis
GO:0030031 cell projection assembly
GO:0030033 microvillus assembly
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031532 actin cytoskeleton reorganization
GO:0032147 activation of protein kinase activity
GO:0032528 microvillus organization
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0033674 positive regulation of kinase activity
GO:0043405 regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043506 regulation of JUN kinase activity
GO:0045860 positive regulation of protein kinase activity
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0046777 protein autophosphorylation
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050773 regulation of dendrite development
GO:0051403 stress-activated MAPK cascade
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0198738 cell-cell signaling by wnt
GO:1990778 protein localization to cell periphery
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0005057 receptor signaling protein activity
Cellular Component GO:0016324 apical plasma membrane
GO:0045177 apical part of cell
GO:0055037 recycling endosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-2559580: Oxidative Stress Induced Senescence
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNIK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNIK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNIK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1490.733
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.6780.146
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9650.264
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.110.709
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.010.996
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.260.925
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4620.29
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6180.591
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2660.838
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2670.762
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5350.682
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4330.00804
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNIK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.67.4-4.80.565
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 2213015.4-15.40.131
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNIK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNIK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNIK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNIK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNIK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNIK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNIK
NameTRAF2 and NCK interacting kinase
Aliases KIAA0551; TRAF2 and NCK-interacting protein kinase
Chromosomal Location3q26.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNIK collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.